VIBERZI™ - A New Treatment for Irritable Bowel Syndrome with Diarrhea (IBS-D)

Drug Review: Volume 17, Issue 8 - Download PDF

VIBERZI™ is a new, first-in-class medication for the treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D). In Canada, IBS-D affects as many as 13–20% of the population. IBS-D is a chronic condition that causes frequent episodes of diarrhea along with abdominal pain and/or discomfort. Symptoms of IBS-D occur unpredictably, which can be distressing for patients.

Current treatment options for IBS-D are very limited. Initial therapy includes dietary and lifestyle modifications with antidiarrheal medications such as loperamide which is available over-the-counter. Loperamide improves diarrhea but does not alleviate abdominal pain or other bothersome symptoms associated with IBS. Other medications can be used for symptom control, including cholestyramine, antispasmodics, and tricyclic antidepressants, however these treatments are not officially approved for IBS-D.

VIBERZI™ is currently the only Health Canada approved medication indicated for IBS-D. Compared to placebo, VIBERZI™ demonstrated superior clinical efficacy in reducing both diarrhea and abdominal pain. VIBERZI™ is generally well-tolerated by patients.

Due to the premium cost associated with VIBERZI™ (approx. $1,700 annually), it is recommended that it be placed under Special Authorization for ClaimSecure groups that subscribe to a Managed Formulary. The Special Authorization process seeks to ensure that VIBERZI™ is only used for members with IBS-D who have failed conventional therapies including diet and lifestyle modifications along with anti-diarrheal medications.

Drug Name

Viberzi®

Drug Ingredients

Eluxadoline 75mg, 100mg

Annual Cost

$1,700

Coverage Details

Fully Covered for Open Drug Formularies

Special Authorization for Managed Formularies

ClaimSecure Inc. reserves the right to amend in part, or in its entirety, its Special Authorization guidelines.

 

References:

VIBERZI® Product Monograph. ALLERGAN Inc. August 2017. Available at: https://allergan-web-cdn-prod.azureedge.net/allergancanadaspecialty/allergancanadaspecialty/media/actavis-canada-specialty/en/products/pms/2017-01-26-viberzi-pm-english.pdf

 

*Based on the Financial Impact Analysis per 100,000 lives covered

©2017 ClaimSecure Inc.